MAP2K7 and breast carcinoma: We propose to investigate the preclinical efficacy of BAY86-9766 (refametinib), an allosteric MEK inhibitor, in models of HER2-positive breast cancer (parental cells (-P)) and in matched models with acquired resistance to trastuzumab (-T and -Res) and lapatinib (-L).